Seeing Machines Regulatory News (SEE)

30 Aug 2006 11:46

Seeing Machines Limited30 August 2006 30 August 2006 SEEING MACHINES LIMITED ("Seeing Machines" or "the Company") GLAUCOMA PROJECT CLINICAL STUDY RESULTS Seeing Machines Limited (AIM: SEE), a leading developer of advanced computerbased imaging software systems, recently concluded the initial phase of a secondclinical study (CT2) of the glaucoma testing device. The purpose of thisinvestigation was to build on the positive results of the CT1 clinical studyannounced in January 2006 by further exploring the operational parameters of thedevice's behaviour in a clinical setting. Importantly, the outcome of this work has clearly illuminated a small number ofdesign parameters that need further investigation prior to the introduction ofthe device. Accordingly an additional clinical study (T13) has been institutedthat will explore these issues allowing for a resumption of the second phase ofthe major CT2 study. The T13 study will commence today. The Company is continuing to progress the other commercialisation activitiesrequired to bring the device to market including regulatory approval, hardwaredesign and software development. All of these activities are supported by therecently awarded Commercial Ready Grant from the Australian Government whichwill allow for the expedited completion of the work. The Company remainscommitted to releasing the glaucoma diagnostic device during 2007. Enquiries: Seeing Machines Limited Insinger de Beaufort Parkgreen Communications Nick Cerneaz, CEO Simon Fox Justine Howarth / Victoria Thomas +61 (0) 2 6125 6501 +44 (0) 20 7190 7018 +44 (0) 20 7493 3713 www.seeingmachines.com This information is provided by RNS The company news service from the London Stock Exchange